NDA bolsters its senior team

Drug development consultancy NDA Group has expanding its service offerings and geographic reach with the addition of three new hires.

Eva Lilienberg joins the group as its new service area lead for integrated development strategy and translational science after 30 years in the industry bringing experience in global product development across US, Europe, Canada and other markets.

Johan Stromquist, chief executive officer of NDA Group, said: “Eva has a strong and varied background supporting multiple programmes in various therapeutic areas across the world’s most important markets.

“Her contributions will help propel client strategy and accelerate programmes across the EU and US, as well as result in new intriguing service offerings that enable innovative companies to navigate the regulatory and market access considerations to meet their goals.”

Lilienberg has served as executive director new products at Merck, Sharp & Dohme (MSD) and has held various positions at Merck Europe, Sanofi and AstraZeneca.

Her new role will see her take responsibility for the group’s strategic development, growth, procedures and overall quality of all services offerings within the areas of translational science and integrated development strategy.

Additionally, Christine Chirdo also joins the team as NDA’s new service area lead for high stakes meetings. She joins from Pfizer where she was director, US strategy category lead and has more than 20 years’ experience in global and US regulatory affairs with a strong focus on several therapeutic areas including pain, as well as consumer experience.

Meanwhile, Barbara Clendenen also joins the group as its business development director from Bioclinica - a provider of speciality outsourced clinical services for the pharmaceutical and biotech industry - where she was director of business development, eHealth solutions. Prior to this she was BD director at Meeting Protocol worldwide and sales director at Quorum Review IRB.